Phreesia (NYSE:PHR) Price Target Raised to $28.00

Phreesia (NYSE:PHR – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $27.00 to $28.00 in a research report report published on Monday, Benzinga reports. They currently have an overweight rating on the stock. Several other analysts also recently commented on PHR. JMP Securities reaffirmed a market outperform rating and set […]

Leave a Reply

Your email address will not be published.

Previous post Perspective Therapeutics’ (CATX) “Overweight” Rating Reiterated at Cantor Fitzgerald
Next post Oramed Pharmaceuticals’ (ORMP) Neutral Rating Reiterated at HC Wainwright